The American Journal of the Medical Sciences, Год журнала: 2025, Номер unknown
Опубликована: Май 1, 2025
Язык: Английский
Journal of Clinical Medicine, Год журнала: 2025, Номер 14(3), С. 1034 - 1034
Опубликована: Фев. 6, 2025
Background/Objectives: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy. Barcelona Clinic Liver Cancer (BCLC) guidelines recommend antiangiogenic agents with immune checkpoint inhibitors as first-line therapy for advanced HCC. We present our experience of treating HCC patients Atezolizumab-Bevacizumab, their response rates, adverse events, survival, and survival predictors. Methods: This retrospective analysis included diagnosed at All India Institute Medical Sciences, New Delhi, between July 2021 April 2024 receiving least one dose Atezolizumab-Bevacizumab. The outcome was overall rate (ORR), comprising complete (CR) partial (PR), per mRECIST criteria. Secondary outcomes were (OS), progression-free (PFS), predictors survival. Results: Sixty-three analyzed {mean age: 56.0 + 12.7 years; 82.5% males}. Forty-three (68.2%) had BCLC stage C Thirty-five (55.5%) belonged to Child-Pugh class A 28 (44.5%) B. At 1 year, OS 39% PFS 27%. Among 43 data radiological response, ORR 48.8% (CR-9.3% PR-39.5%) DCR 62.7% stable disease (SD) in 13.9% patients. PD occurred 37.2% AFP predicted while Adverse events reported 49.2% Conclusions: Our study shows slightly lower than previous studies being important determinant predicts not
Язык: Английский
Процитировано
1
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Фев. 17, 2025
Hepatocellular carcinoma (HCC) is the most prevalent primary liver malignancy and a leading cause of cancer-related deaths globally. The asymptomatic progression early-stage HCC often results in diagnosis at advanced stages, significantly limiting therapeutic options worsening prognosis. Immunotherapy, with immune checkpoint inhibitors (ICIs) forefront, has revolutionized treatment. Nevertheless, tumor heterogeneity, evasion, presence immunosuppressive components within microenvironment (TIME) continue to compromise its efficacy. Furthermore, resistance or non-responsiveness ICIs some patients underscores urgent need unravel complexities TIME design innovative strategies that enhance immunotherapeutic outcomes. Emerging evidence revealed pivotal role N6-methyladenosine (m6A), prominent RNA methylation modification, shaping HCC. By regulating stability translation, m6A influences immune-related factors, including cytokines molecules. This modification governs PD-L1 expression, facilitating escape contributing against ICIs. Advances this field have also identified m6A-related regulators as promising biomarkers for predicting immunotherapy response potential targets optimizing treatment review examines regulatory mechanisms HCC, focus on impact cells cytokine dynamics. It explores targeting pathways improve efficacy outlines emerging directions future research. These insights aim provide foundation developing novel overcome advance
Язык: Английский
Процитировано
0
Cancer Pathogenesis and Therapy, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Discover Oncology, Год журнала: 2025, Номер 16(1)
Опубликована: Апрель 17, 2025
Язык: Английский
Процитировано
0
Cancer Immunology Immunotherapy, Год журнала: 2025, Номер 74(6)
Опубликована: Апрель 28, 2025
This study retrospectively evaluated the safety and efficacy of cadonilimab combined with tyrosine kinase inhibitors (TKI) for treatment unresectable hepatocellular carcinoma (uHCC). Seventy-eight patients who received + TKI were included; 42 36 it as first-line (1 L) second-line above (≥ 2 systemic treatment, respectively. Besides, ninety-five PD-1 inhibitor treatments included. Safety was primary endpoint; secondary endpoints overall survival (OS), progression-free (PFS), objective response rate (ORR), disease control (DCR). Treatment-related adverse events (TRAEs) any grade occurred in 84.6% patients, ≥ 3 20.5%. In a Child-Pugh score 8 (CP 8), TRAEs 88.2%, 20.6%. The cohort's median (mPFS) 3.6 months, whereas (mOS) 8.8 months. 1 L group, mPFS 6.7 months versus 2.3 L. mOS 13.7 3.2 For CP < 8, 7.6 not reached; had 5.2 5.6 L, 3.1 months; 1.4 2.2 After propensity matching (PSM), incidence 77.1%, accounting 17.1% group. PD-1/CTLA-4 80.0%, that 17.1%. group 3.3 Cadonilimab showed favorable trend efficacy, especially when applied therapy uHCC. offers clinical reference its use uHCC therapy, particularly advanced liver dysfunction.
Язык: Английский
Процитировано
0
Frontiers in Oncology, Год журнала: 2025, Номер 15
Опубликована: Май 1, 2025
Current large clinical trials mainly focus on Child-Pugh A (CP-A) stage hepatocellular carcinoma (HCC) patients, with limited data CP-B patients especially those classified as B8-9, whose treatment needs remain inadequately addressed. This study aims to evaluate the safety efficacy of interventional treatments, or without targeted-immunotherapy and characteristics HCC receiving. single-center retrospective investigation incorporated 119 were stratified into two cohorts: therapy cohort (42) combined targeted immunotherapy (77). The data, overall survival (OS), progression-free (PFS), therapeutic both groups meticulously recorded comprehensively analyzed. Survival disparities statistically compared employing Kaplan-Meier analysis method log-rank test. Tumor remission was appraised in accordance RECIST 1.1 mRECIST criteria. Independent influencing factors discerned through multifactorial COX regression analysis. Subsequently, prediction models constructed generate column line graphs, profiles adverse events associated diverse modalities also evaluated. grade included, median (mOS) who received combination 21.4 months (vs 13.2, P=0.038) superior that therapy, (mPFS) 12.7 10.9 months, P=0.183) not significantly improved. OS group B7 24.6 11.9, P=0.006) intervention, while there no significant improvement B8-9. objective rate (ORR) higher than intervention (RECIST: 32.5% vs 11.9%, P = 0.014; mRECIST: 48.1% 23.8%, 0.010). Except for score progression (P 0.003), difference occurrence all-grade ≥grade 3 > 0.05). Interventional can be a safe effective B setting controlled liver function impairment.
Язык: Английский
Процитировано
0
Frontiers in Oncology, Год журнала: 2025, Номер 15
Опубликована: Май 9, 2025
Introduction Increasing evidence highlights the pivotal role of RNA methylation and miRNAs in hepatocellular carcinoma (HCC). However, risk associated with methylation-related (RMRMs) HCC immune microenvironment remains largely unknown. Here, we predicted correlation between RMRM cell infiltration using machine learning. Methods MiRNA sequencing data was used to identify RMRMs. A score model developed utilizing four RMRMs, including miR-551a, miR-4739, miR-326, miR-210-3p. Results Patients high-risk scores exhibited poorer prognoses. Single-cell (scRNA-seq) analysis revealed group increased levels several subtypes, myeloid-derived suppressor (MDSC), macrophage, T cells. The integration scRNA-seq bulk RNA-seq showed decreased TIDE patients elevated Macro-secreted phosphoprotein 1 (SPP1), MDSC-meiotic nuclear divisions (MND1), γδ cells, Macro-complement C1q C chain (C1QC) adverse prognosis. ScRNA-seq spatial transcriptomics unveiled distribution RMRMs their subtype localization. Risk model-based clustering samples that cluster 2, characterized by a higher score, correlated prognosis reduced stromal scores. In vitro, overexpression miR-4739 Huh-7 cells significantly induced SPP1 + macrophages, culture medium derived from macrophages further promoted proliferation migration Furthermore, m1A inhibiting tRNA methyltransferase 61A (TRMT61A) expression. Discussion Our study reveals could effectively predict HCC, regulated miR-4739-RNA promote These results highlight potential predicting HCC.
Язык: Английский
Процитировано
0
The American Journal of the Medical Sciences, Год журнала: 2025, Номер unknown
Опубликована: Май 1, 2025
Язык: Английский
Процитировано
0